<doc>
  <docmeta id="113s504is">
    <bill congress="113" type="s" number="504" version="is"/>
    <revision size="14749" annotations="0" status="complete" id="4" commit-time="2013-08-07T19:44:16Z" committer="mbohmer" doc="113s504is/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S504 IS: Fair And Immediate Release of Generic Drugs Act </dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-03-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 504</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130307">March 7, 2013</action-date>
			<action-desc>
        <sponsor name-id="S332">Mr. Franken</sponsor> (for
			 himself, <cosponsor name-id="S299">Mr. Vitter</cosponsor>,
			 <cosponsor name-id="S253">Mr. Durbin</cosponsor>, <cosponsor name-id="S324">Mrs. Shaheen</cosponsor>, and <cosponsor name-id="S313">Mr.
			 Sanders</cosponsor>) introduced the following bill; which was read twice and
			 referred to the <committee-name committee-id="SSHR00">Committee on Health,
			 Education, Labor, and Pensions</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to
		  ensure that valid generic drugs may enter the market.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one">
      <enum>1.</enum>
      <header>Short
			 title</header>
      <text display-inline="no-display-inline">This Act may be cited as
			 the <quote>
          <short-title>Fair And Immediate Release of
			 Generic Drugs Act </short-title>
        </quote> or the <quote>
          <short-title>FAIR Generics Act</short-title>
        </quote>.</text>
		</section>
    <section id="ID11c8c50a21c74d90849d012e200ec243">
      <enum>2.</enum>
      <header>180-Day
			 exclusivity period amendments regarding first applicant status</header>
			<subsection id="ID6330cbed4e2a4d69910df9758f1950aa">
        <enum>(a)</enum>
        <header>Amendments to
			 Federal Food, Drug, and Cosmetic Act</header>
				<paragraph id="IDbc6d731c151c43a88c1217124c6e7504">
          <enum>(1)</enum>
          <header>In
			 general</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B">Section 505(j)(5)(B) of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
                <cato:entity-ref entity-type="uscode" value="usc/21/355/j/5/B">21 U.S.C. 355(j)(5)(B)</cato:entity-ref>
              </external-xref>)</cato:entity> is amended—</text>
					<subparagraph id="id7189819659D84B4E825654171F2A4802">
            <enum>(A)</enum>
            <text>in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:iv/scl:II">clause
			 (iv)(II)</cato:entity-ref>—</text>
						<clause id="id75184DCBDD8141FD9731CB9FA27B929E">
              <enum>(i)</enum>
              <text>by
			 striking <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:iv/scl:II/i:bb">item (bb)</cato:entity-ref>; and</text>
						</clause>
            <clause id="idDF4638148C314F7DAFB5222A16DF8E6B">
              <enum>(ii)</enum>
              <text>by
			 redesignating <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:iv/scl:II/i:cc, dd">items (cc) and (dd)</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:iv/scl:II/i:bb, cc" proposed="true">items (bb) and (cc)</cato:entity-ref>, respectively;
			 and</text>
						</clause>
          </subparagraph>
          <subparagraph id="idE1ADF87F66434238B999027300C82A34">
            <enum>(B)</enum>
            <text>by adding at the
			 end the following:</text>
						<quoted-block display-inline="no-display-inline" id="id062F1252272E409EABD43240FEBE52DC" style="OLC">
							<clause id="idFC020D43F9E24E30B1644B9D46E7DF1D" indent="up3">
                <enum>(v)</enum>
                <header>First applicant
				defined</header>
                <text>As used in this subsection, the term <term>first
				applicant</term> means an applicant—</text>
								<subclause id="idAC05111366AF4C3CB46A2FBAF22FE08C">
                  <enum>(I)</enum>
                  <item commented="no" display-inline="yes-display-inline" id="id511902278CDE4F2FA469536435C660E5">
                    <enum>(aa)</enum>
                    <text>that, on the first day
				on which a substantially complete application containing a certification
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV">paragraph (2)(A)(vii)(IV)</cato:entity-ref> is submitted for approval of a drug,
				submits a substantially complete application that contains and lawfully
				maintains a certification described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV">paragraph (2)(A)(vii)(IV)</cato:entity-ref> for the drug;
				and</text>
									</item>
                  <item id="idC1F279C52DA7419596F2E10BF86F5DC3" indent="up1">
                    <enum>(bb)</enum>
                    <text>that has not entered into a
				disqualifying agreement described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:II" proposed="true">clause (vii)(II)</cato:entity-ref>; or</text>
									</item>
                </subclause>
                <subclause id="id61033FA684994005B76A355D49F9DFEE">
                  <enum>(II)</enum>
                  <item commented="no" display-inline="yes-display-inline" id="idF657711E907E4FEBB26A2B3E89DBE9E3">
                    <enum>(aa)</enum>
                    <text>for the drug that is
				not described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:I" proposed="true">subclause (I)</cato:entity-ref> and that, with respect to the applicant and
				drug, each requirement described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vi" proposed="true">clause (vi)</cato:entity-ref> is satisfied; and</text>
									</item>
                  <item id="id6A17EC58D89A4680B169EB6655A202C1" indent="up1">
                    <enum>(bb)</enum>
                    <text>that has not entered into a
				disqualifying agreement described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:II" proposed="true">clause (vii)(II)</cato:entity-ref>.</text>
									</item>
                </subclause>
              </clause>
              <clause id="id9C7D942107E74E23939E3F2AB9E76CBD" indent="up3">
                <enum>(vi)</enum>
                <header>Requirement</header>
                <text>The
				requirements described in this clause are the following:</text>
								<subclause id="id17C91423D5C7410B83FD8451EFCBCEB3">
                  <enum>(I)</enum>
                  <text>The applicant described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:II" proposed="true">clause
				(v)(II)</cato:entity-ref> submitted and lawfully maintains a certification described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV">paragraph
				(2)(A)(vii)(IV)</cato:entity-ref> or a statement described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:viii">paragraph (2)(A)(viii)</cato:entity-ref> for each
				unexpired patent for which a first applicant described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:I" proposed="true">clause (v)(I)</cato:entity-ref> had
				submitted a certification described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV">paragraph (2)(A)(vii)(IV)</cato:entity-ref> on the first
				day on which a substantially complete application con­tain­ing such a
				certification was submitted.</text>
								</subclause>
                <subclause id="id88EAA3A7E5CF4AD3B24BB5F47EE28C30">
                  <enum>(II)</enum>
                  <text>With regard to each such unexpired
				patent for which the applicant described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:II" proposed="true">clause (v)(II)</cato:entity-ref> submitted a
				certification described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:2/sp:A/cl:vii/scl:IV" proposed="true">paragraph (2)(A)(vii)(IV)</cato:entity-ref>, no action for patent
				infringement was brought against such applicant within the 45-day period
				specified in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:iii">paragraph (5)(B)(iii)</cato:entity-ref>; or if an action was brought within such
				time period, such an action was withdrawn or dismissed by a court (including a
				district court) without a decision that the patent was valid and infringed; or
				if an action was brought within such time period and was not withdrawn or so
				dismissed, such applicant has obtained the decision of a court (including a
				district court) that the patent is invalid or not infringed (including any
				substantive determination that there is no cause of action for patent
				infringement or invalidity, and including a settlement order or consent decree
				signed and entered by the court stating that the patent is invalid or not
				infringed).</text>
								</subclause>
                <subclause id="id6C8EDF3813A54DFBBC0E0A6512B87EB9">
                  <enum>(III)</enum>
                  <text>If an applicant described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:I" proposed="true">clause
				(v)(I)</cato:entity-ref> has begun commercial marketing of such drug, the applicant described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:II" proposed="true">clause (v)(II)</cato:entity-ref> does not begin commercial marketing of such drug until the date
				that is 30 days after the date on which the applicant described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:I" proposed="true">clause
				(v)(I)</cato:entity-ref> began such commercial
				marketing.</text>
								</subclause>
              </clause>
              <after-quoted-block>.</after-quoted-block>
            </quoted-block>
					</subparagraph>
        </paragraph>
        <paragraph id="IDc4a27ff356014a90822eaefdf619e67c">
          <enum>(2)</enum>
          <header>Conforming
			 amendment</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:D/cl:i/scl:IV">Section 505(j)(5)(D)(i)(IV) of such Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/j/5/D/i/IV">21 U.S.C.
			 355(j)(5)(D)(i)(IV)</cato:entity-ref>)</cato:entity> is amended by striking <quote>The first applicant</quote>
			 and inserting <quote>The first applicant, as defined in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:v/scl:I">subparagraph
			 (B)(v)(I)</cato:entity-ref>,</quote>.</text>
				</paragraph>
      </subsection>
      <subsection id="ID7877ead9b43446278c9a46d5cbb98204">
        <enum>(b)</enum>
        <header>Applicability</header>
        <text>The
			 amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:2/ss:a" proposed="true">subsection (a)</cato:entity-ref> shall apply only with respect to an
			 application filed under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">section 505(j) of the Federal Food, Drug, and Cosmetic
			 Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
              <cato:entity-ref entity-type="uscode" value="usc/21/355/j">21 U.S.C. 355(j)</cato:entity-ref>
            </external-xref>)</cato:entity> to which the amendments made by <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1102/ss:a">section 1102(a) of the
			 Medicare Prescription Drug, Improvement, and Modernization Act of 2003</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/108/173">Public
			 Law 108–173</cato:entity-ref>)</cato:entity> apply.</text>
			</subsection>
    </section>
    <section id="IDaa05ca3397834cd18cc37eaa41730c75">
      <enum>3.</enum>
      <header>180-Day
			 exclusivity period amendments regarding agreements to defer commercial
			 marketing</header>
			<subsection id="IDa57973e12bf7408bb4e4ca2272a32c2f">
        <enum>(a)</enum>
        <header>Amendments to
			 Federal Food, Drug, and Cosmetic Act</header>
				<paragraph id="ID2b6f4468ee824d7d8d1f500bb607b062">
          <enum>(1)</enum>
          <header>Limitations on
			 agreements to defer commercial marketing date</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B">Section
			 505(j)(5)(B) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/j/5/B">21 U.S.C.
			 355(j)(5)(B)</cato:entity-ref>)</cato:entity>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:2" proposed="true">section 2</cato:entity-ref>, is further amended by adding at the end
			 the following:</text>
					<quoted-block display-inline="no-display-inline" id="id4C3D872B8665425B8C7A3E91481B5062" style="OLC">
						<clause id="ID8a16b9ede9a54dfbaaef407fdd8bcb07" indent="up2">
              <enum>(vii)</enum>
              <header>Agreement by first applicant to
				defer commercial marketing; limitation on acceleration of deferred commercial
				marketing date</header>
							<subclause id="id3BCBB59EA21A43BC92585341D54E464F">
                <enum>(I)</enum>
                <header>Agreement to defer approval or
				commercial marketing date</header>
                <text>An agreement described in this
				subclause is an agreement between a first applicant and the holder of the
				application for the listed drug or an owner of one or more of the patents as to
				which any applicant submitted a certification qualifying such applicant for the
				180-day exclusivity period whereby that applicant agrees, directly or
				indirectly, (aa) not to seek an approval of its application that is made
				effective on the earliest possible date under this subparagraph, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F">subparagraph
				(F) of this paragraph</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">section 505A</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section 527</cato:entity-ref>, (bb) not to begin the
				commercial marketing of its drug on the earliest possible date after receiving
				an approval of its application that is made effective under this subparagraph,
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F">subparagraph (F) of this paragraph</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">section 505A</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section 527</cato:entity-ref>, or (cc) to
				both <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:I/i:aa" proposed="true">items (aa)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:I/i:bb" proposed="true">(bb)</cato:entity-ref>.</text>
							</subclause>
              <subclause id="id2100E98E2D8C4787B83D9027C112363A">
                <enum>(II)</enum>
                <header>Agreement that disqualifies
				applicant from first applicant status</header>
                <text>An agreement described in
				this subclause is an agreement between an applicant and the holder of the
				application for the listed drug or an owner of one or more of the patents as to
				which any applicant submitted a certification qualifying such applicant for the
				180-day exclusivity period whereby that applicant agrees, directly or
				indirectly, not to seek an approval of its application or not to begin the
				commercial marketing of its drug until a date that is after the expiration of
				the 180-day exclusivity period awarded to another applicant with respect to
				such drug (without regard to whether such 180-day exclusivity period is awarded
				before or after the date of the agreement).</text>
							</subclause>
            </clause>
            <clause id="idF68A0ED0F925446088097254CDE8F268" indent="up2">
              <enum>(viii)</enum>
              <header>Limitation on
				acceleration</header>
              <text>If an agreement described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:I" proposed="true">clause (vii)(I)</cato:entity-ref>
				includes more than 1 possible date when an applicant may seek an approval of
				its application or begin the commercial marketing of its drug—</text>
							<subclause id="id796AC24DE5064AE89C4452D890D9F9D0">
                <enum>(I)</enum>
                <text>the applicant may seek an approval
				of its application or begin such commercial marketing on the date that is the
				earlier of—</text>
								<item id="id00286B1642FE4134BCF26D96F4ACD759">
                  <enum>(aa)</enum>
                  <text>the latest date set forth in the
				agreement on which that applicant can receive an approval that is made
				effective under this subparagraph, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F">subparagraph (F) of this paragraph</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">section
				505A</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section 527</cato:entity-ref>, or begin the commercial marketing of such drug, without
				regard to any other provision of such agreement pursuant to which the
				commercial marketing could begin on an earlier date; or</text>
								</item>
                <item id="id95ACCEA6874C4196BA5DFFD3F4BEB518">
                  <enum>(bb)</enum>
                  <text>180 days after another first applicant
				begins commercial marketing of such drug; and</text>
								</item>
              </subclause>
              <subclause id="id90E43F67E8E14ECE88A62341D3367419">
                <enum>(II)</enum>
                <text>the latest date set forth in the
				agreement on which that applicant can receive an approval that is made
				effective under this subparagraph, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:F">subparagraph (F) of this paragraph</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505A">section
				505A</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:527">section 527</cato:entity-ref>, or begin the commercial marketing of such drug, without
				regard to any other provision of such agreement pursuant to which commercial
				marketing could begin on an earlier date, shall be the date used to determine
				whether an applicant is disqualified from first applicant status pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:II" proposed="true">clause
				(vii)(II)</cato:entity-ref>.</text>
							</subclause>
            </clause>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="ID274147e1bc1e4e829fb9ba5cbba0abfc">
          <enum>(2)</enum>
          <header>Notification of
			 FDA</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">Section 505(j) of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/355">
                <cato:entity-ref entity-type="uscode" value="usc/21/355/j">21 U.S.C. 355(j)</cato:entity-ref>
              </external-xref>)</cato:entity> is amended by
			 adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="id92543B96C89246AA96E0FA28D7610EC9" style="OLC">
						<paragraph id="id258EF44DD8EC4556BAFD25E519E7C365" indent="up1">
              <enum>(11)</enum>
              <subparagraph commented="no" display-inline="yes-display-inline" id="id8BA2581345A9494FAD6142F15879D519">
                <enum>(A)</enum>
                <text>The holder of an
				abbreviated application under this subsection shall submit to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a
				notification that includes—</text>
								<clause id="id97B739EBA40E4368A07CA39B43D263FB" indent="up1">
                  <enum>(i)</enum>
                  <subclause commented="no" display-inline="yes-display-inline" id="id6BC12AC1CD5540A098FA669F8DCF6A2E">
                    <enum>(I)</enum>
                    <text>the text of any
				agreement entered into by such holder described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:I">paragraph (5)(B)(vii)(I)</cato:entity-ref>;
				or</text>
									</subclause>
                  <subclause id="id48EF35BC525A40DCA8E088C294D5A294" indent="up1">
                    <enum>(II)</enum>
                    <text>if such an agreement has not been
				reduced to text, a written detailed description of such agreement that is
				sufficient to disclose all the terms and conditions of the agreement;
				and</text>
									</subclause>
                </clause>
                <clause id="id7810422424D24170B4BFEC0DF5F84D0E" indent="up1">
                  <enum>(ii)</enum>
                  <text>the text, or a written detailed
				description in the event of an agreement that has not been reduced to text, of
				any other agreements that are contingent upon, provide a contingent condition
				for, or are otherwise related to an agreement described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:11/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
              <subparagraph id="id5C9D77465B32412C8F0B9F5F7479BE38" indent="up1">
                <enum>(B)</enum>
                <text>The notification described under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:11/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be submitted not later than 10 business days after
				execution of the agreement described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:11/sp:A/cl:i" proposed="true">subparagraph (A)(i)</cato:entity-ref>. Such notification
				is in addition to any notification required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1112">section 1112 of the Medicare
				Prescription Drug, Improvement, and Modernization Act of 2003</cato:entity-ref>.</text>
							</subparagraph>
              <subparagraph id="id05D23BC53A8D4FCE91C31B1B8BA03DC9" indent="up1">
                <enum>(C)</enum>
                <text>Any information or documentary
				material filed with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> pursuant to this paragraph shall be exempt
				from disclosure under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/5/552">
                    <external-xref legal-doc="usc" parsable-cite="usc/5/552">section 552</external-xref> of title 5, United States Code</cato:entity-ref>, and no such
				information or documentary material may be made public, except as may be
				relevant to any administrative or judicial action or proceeding. Nothing in
				this paragraph is intended to prevent disclosure to either body of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>
				or to any duly authorized committee or subcommittee of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
        <paragraph id="IDd27f5d987fc5464eab7db22282cbb94c">
          <enum>(3)</enum>
          <header>Prohibited
			 acts</header>
          <text>
            <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/ss:e">Section 301(e) of such Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
                <cato:entity-ref entity-type="uscode" value="usc/21/331/e">21 U.S.C. 331(e)</cato:entity-ref>
              </external-xref>)</cato:entity> is amended by
			 striking <quote>505 (i) or (k)</quote> and inserting <quote>505 (i), (j)(11),
			 or (k)</quote>.</text>
				</paragraph>
      </subsection>
      <subsection id="id16BEAD7F09334ACA9C246D678D72CBA6">
        <enum>(b)</enum>
        <header>Infringement of
			 patent</header>
        <text display-inline="yes-display-inline">
          <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc/35/271/e">Section 271(e) of
			 title 35, United States Code</cato:entity-ref>, is amended by adding at the end the
			 following:</text>
				<quoted-block display-inline="no-display-inline" id="id1A4A441502CA4B5CB0C8588CFF4F54D9" style="OLC">
					<paragraph commented="no" id="id083C8BD9829A4876B838C909B072A884" indent="up1">
            <enum>(7)</enum>
            <text>The exclusive remedy under this
				section for an infringement of a patent for which the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and
				Human Services</cato:entity-ref> has published information pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:b/p:1">subsection (b)(1)</cato:entity-ref> or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:2">(c)(2) of section 505 of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> shall be an
				action brought under this subsection within the 45-day period described in
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:iii">subsection (j)(5)(B)(iii)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:c/p:3/sp:C">(c)(3)(C) of section 505 of the Federal Food,
				Drug, and Cosmetic
				Act</cato:entity-ref>.</text>
					</paragraph>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="ID0ea03683aa68491d9b0e96bcf486d8b1">
        <enum>(c)</enum>
        <header>Applicability</header>
				<paragraph id="id969843E1653B4421917CDBDDEA094CA1">
          <enum>(1)</enum>
          <header>Limitations on
			 acceleration of deferred commercial marketing date</header>
          <text>The amendment
			 made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:3/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref> shall apply only with respect to—</text>
					<subparagraph id="id8950AB1A3BF64B558BE86764F142AD6F">
            <enum>(A)</enum>
            <text>an application
			 filed under <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j">section 505(j) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<cato:entity-ref entity-type="uscode" value="usc/21/355/j">21
			 U.S.C. 355(j)</cato:entity-ref>)</cato:entity> to which the amendments made by <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
                <cato:entity-ref entity-type="act" value="Medicare Prescription Drug, Improvement, and Modernization Act of 2003/s:1102/ss:a">section 1102(a) of the Medicare
			 Prescription Drug, Improvement, and Modernization Act of 2003</cato:entity-ref> (<cato:entity-ref entity-type="public-law" value="public-law/108/173">Public Law
			 108–173</cato:entity-ref>)</cato:entity> apply; and</text>
					</subparagraph>
          <subparagraph id="IDb86db9e1370c4c24908624d69993b4b8">
            <enum>(B)</enum>
            <text>an agreement
			 described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:I" proposed="true">section 505(j)(5)(B)(vii)(I) of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (as added by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:2/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref>) executed after the date of
			 enactment of this Act.</text>
					</subparagraph>
        </paragraph>
        <paragraph id="ID1712456ef18c4b7c8e9569acd5b2fa47">
          <enum>(2)</enum>
          <header>Notification of
			 FDA</header>
          <text>The amendments made by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:2/ss:a/p:2" proposed="true">paragraphs (2)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:2/ss:a/p:3" proposed="true">(3) of subsection
			 (a)</cato:entity-ref> shall apply only with respect to an agreement described under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505/ss:j/p:5/sp:B/cl:vii/scl:I" proposed="true">section
			 505(j)(5)(B)(vii)(I) of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (as added by
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Fair And Immediate Release of Generic Drugs Act/s:2/ss:a/p:1" proposed="true">subsection (a)(1)</cato:entity-ref>) executed after the date of enactment of this Act.</text>
				</paragraph>
      </subsection>
    </section>
  </legis-body>
</bill>
</doc>